Clinical Research of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy

Clinical Research of the Molecular Phenotype Distribution of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03668522

Enrollment

Registered

2018-09-12

Start date

2018-09-30

Completion date

2020-01-31

Last updated

2018-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Tumor

Keywords

H3F3AK27M

Brief summary

H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.

Interventions

OTHERGenetic testing

To determine whether H3F3AK27M exist in spinal glioma

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation.

Exclusion criteria

* The tumor is recurrent or has been treated before operation.

Design outcomes

Primary

Measure	Time frame	Description
positive	through study completion, an average of 1 year	positive of H3F3AK27M

Countries

China

Contacts

Primary ContactLu Yuntao, M.D., Ph.D

lllu2000@163.com13632101002

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026